Evidence map›Paper›PMID 34758831›Full record

ReviewCost effectiveness and resource allocation : C/E2021

Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting.

Charles C Maponga, Tsitsi G Monera-Penduka, Takudzwa J Mtisi, Robin Difrancesco, Faithful Makita-Chingombe, Fine Mazambara, Kathleen Tooley, Tinashe Mudzviti, Gene D Morse

Open access · goldAbstract readReview
In one paragraph

Review in Cost effectiveness and resource allocation : C/E, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Charles C MapongaInternational Pharmacotherapy Education and Research Initiative (IPERI), Department of Pharmacy and Pharmaceutical Science, University of Zimbabwe Faculty of Medicine and Health Sciences, c/o Drug and Toxicology Information Services (DaTIS), PO Box A178, Avondale Harare, Zimbabwe.
Tsitsi G Monera-PendukaInternational Pharmacotherapy Education and Research Initiative (IPERI), Department of Pharmacy and Pharmaceutical Science, University of Zimbabwe Faculty of Medicine and Health Sciences, c/o Drug and Toxicology Information Services (DaTIS), PO Box A178, Avondale Harare, Zimbabwe. moneratg@yahoo.co.uk.ORCID http://orcid.org/0000-0002-1572-6790
Takudzwa J MtisiInternational Pharmacotherapy Education and Research Initiative (IPERI), Department of Pharmacy and Pharmaceutical Science, University of Zimbabwe Faculty of Medicine and Health Sciences, c/o Drug and Toxicology Information Services (DaTIS), PO Box A178, Avondale Harare, Zimbabwe.
Robin DifrancescoCenter for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences, The State University of New York, Buffalo, NY, USA.
Faithful Makita-ChingombeInternational Pharmacotherapy Education and Research Initiative (IPERI), Department of Pharmacy and Pharmaceutical Science, University of Zimbabwe Faculty of Medicine and Health Sciences, c/o Drug and Toxicology Information Services (DaTIS), PO Box A178, Avondale Harare, Zimbabwe.
Fine MazambaraInternational Pharmacotherapy Education and Research Initiative (IPERI), Department of Pharmacy and Pharmaceutical Science, University of Zimbabwe Faculty of Medicine and Health Sciences, c/o Drug and Toxicology Information Services (DaTIS), PO Box A178, Avondale Harare, Zimbabwe.
Kathleen TooleyCenter for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences, The State University of New York, Buffalo, NY, USA.
Tinashe MudzvitiInternational Pharmacotherapy Education and Research Initiative (IPERI), Department of Pharmacy and Pharmaceutical Science, University of Zimbabwe Faculty of Medicine and Health Sciences, c/o Drug and Toxicology Information Services (DaTIS), PO Box A178, Avondale Harare, Zimbabwe.
Gene D MorseCenter for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences, The State University of New York, Buffalo, NY, USA.
University of Zimbabwe · ZWUniversity at Buffalo, State University of New York · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
HIV Research Training ProgramD43TW010313 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Charles Enos Chiedza Maponga, Gene D. Morse · 2016 to 2026
$3.2M
TDM &Drug Interactions in HIVinfected Substance AbusersR01DA015024 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MORSE, GENE D · 2003 to 2007
$2.9M
Antiretroviral Pharmacology Training in Resource Poor CountriesD43TW007991 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MORSE, GENE D. · 2009 to 2015
$1.6M
HUMAN CYTOTOXIC T CELL RESPONSES TO TRYPANOSOMA CRUZIR03TW000799 · FIC · UNIVERSITY OF GEORGIA (UGA) · PI TARLETON, RICK L · 1997 to 1998
–
Center for AIDS Research, University of Rochester Medical Center P30AI078498FIC NIH HHS D43TW007991FIC NIH HHS D43TW00799101A2S1FIC NIH HHS D43 TW010313FIC NIH HHS D43TW010313FIC NIH HHS D43 TW010540FIC NIH HHS SA5335-32119National Institute of Allergy and Infectious Diseases AI068634National Institute of Allergy and Infectious Diseases UM1AI068636National Institute of Allergy and Infectious Diseases UM1AI106701NCATS NIH HHS UL1 TR001412NCATS NIH HHS UL1TR001412NIAID NIH HHS HHSN272200800019CNIAID NIH HHS HHSN272201500006CNIAID NIH HHS P30 AI078498NIDA NIH HHS R01 DA015024NIDA NIH HHS R01DA015024-03S2
6 · The paper itself

Abstract

While important advances have been made in the prevention and treatment of Human Immunodeficiency Virus (HIV) infection, limited expertise and resource constraints to effectively manage rollout of HIV programs often contribute to poor treatment outcomes in Sub-Saharan Africa. In 1998, the University of Zimbabwe (UZ) and the University at Buffalo, State University of New York (UB), developed a collaborative clinical pharmacology capacity building program in Zimbabwe to train the next generation of HIV researchers and support rollout of the national HIV program. The collaboration was funded by research and training grants that were competitively acquired through United States of America government funding mechanisms, between 1998 and 2016. Thirty-eight research fellows were trained and a specialty clinical pharmacology laboratory was established during this period. Knowledge and skills transfer were achieved through faculty and student exchange visits. Scientific dissemination output included sixty-two scholarly publications that influenced three national policies and provided development of guidelines for strategic leadership for an HIV infection-patient adherence support group. The clinical pharmacology capacity building program trained fellows that were subsequently incorporated into the national technical working group at the Ministry of Health and Child Care, who are responsible for optimizing HIV treatment guidelines in Zimbabwe. Despite serious economic challenges, consistent collaboration between UZ and UB strengthened UZ faculty scholarly capacity, retention of HIV clinical research workforce was achieved, and the program made additional contributions toward optimization of antiretroviral therapy in Zimbabwe.

Indexed as

Capacity buildingClinical pharmacologyCollaborationHIVResearchResource-limited

Identifiers

PMID34758831
PMCPMC8579570
OpenAlexW3212605989

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.